MTC Versus FMT in for RCDI

Inclusion Criteria: * Ages eligible for study: 18 years and older * Able and willing to provide written informed consent * History of recurrent CDI defined as 2 episodes of CDI occurring within the previous 6 months (inclusive of the current episode) * Subjects with a qualifying recurrent CDI episode, defined as: * History of diarrhea (\>=3 unformed stools per day for 2 or more consecutive days that is clinically consistent with CDI * Documented positive stool test by local laboratory for toxigenic C. difficile (toxin EIA or PCR-based testing) for the current CDI episode within 60 days prior to randomization. * Received a course of standard-of-care (SOC) CDI antibiotics for the most recent CDI episode (for 10 to 42 days, with exact duration, antibiotic type and dose at the discretion of the Investigator) * Demonstrated adequate clinical response, defined as \<= 3 unformed stools per day for 2 or more consecutive days during SOC CDI antibiotics prior to randomization. * CDI symptoms started within 60 days prior to randomization. Exclusion Criteria: * Female subjects who are pregnant or breastfeeding or are planning to become pregnant during the study. * Women with reproductive potential should use a reliable method of birth control: * Consistent use of an approved hormonal contraception (birth control pill/patches, rings); An intrauterine device (IUD); Contraceptive injection (Depo-Provera); Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam); Sexual abstinence (no sexual intercourse) or Sterilization * Known or suspected toxic megacolon, ileus or bowel obstruction at the time of enrollment. * Subjects with active gastroenteritis due to infectious causes other than CDI * Subjects with allergies to ingredients present in the investigational product * Prior participation in studies of investigational live biotherapeutic products or FMT within the last 6 months. * Major gastrointestinal surgery within the last 3 months before enrollment. * Use of drugs that alter gut motility. * History of acute leukemia or hematopoietic stem cell transplantation or myelosuppressive chemotherapy within 2 months prior to enrollment. * Unable or unwilling to undergo a colonoscopy * Inpatient status, though patients can be screened while inpatients, the must be outpatient for the planned colonoscopy. * Anticipated immediate or upcoming surgery within 30 days * Need for continued non-anti-CDI antibiotic therapy * History of total proctocolectomy * Patients who are unable to give informed consent * Participation in a clinical trial in the preceding 30 days or simultaneously during this trial * Severe food allergy (anaphylaxis or anaphylactoid-like reaction) * Life expectancy \< 6 months * Unable to adhere to protocol requirements * Patient who have received an FMT in the past year * Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines that it will put the subject at greater risk from FMT * Clinically significant abnormal lab values including but not limited to WBC \>15 x 103/mm3, ANC \<0.5 x 103/mm3, or laboratory evidence of acute kidney injury at Investigator's discretion, at screening * If a patient is heavily immunosuppressed and is negative for CMV or EBV